Zhejiang ChiMin Pharmaceutical Co Ltd (603222)

Currency in CNY
7.07
+0.01(+0.14%)
Closed·

603222 Financial Summary

Key Ratios

P/E Ratio-42.99
Price/Book2.22
Debt / Equity47.98%
Return on Equity-5.37%
Dividend Yield0.00%
EBITDA54.05M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Earnings

Latest Release
May 05, 2025
EPS / Forecast
-0.03 / --
Revenue / Forecast
181.02M / --
EPS Revisions
Last 90 days

FAQ

What were Zhejiang ChiMin Pharm's earnings for the latest quarter?

The Zhejiang ChiMin Pharm EPS (TTM) is -0.17. Zhejiang ChiMin Pharm reported sales of 181.02, net income of -13.64, and EPS of -0.03 for the latest quarter.

What was Zhejiang ChiMin Pharm's net income for the latest quarter?

Zhejiang ChiMin Pharm's net income for the latest quarter was -13.64.

How did Zhejiang ChiMin Pharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 93.06 in the previous quarter to 181.02 in the latest quarter, and net income moved from -88.13 to -13.64 compared to the previous quarter.

What is Zhejiang ChiMin Pharm's net profit margin on a TTM basis?

Zhejiang ChiMin Pharm's trailing twelve months (TTM) net profit margin is -7.70%.

How does Zhejiang ChiMin Pharm's debt to equity ratio compare to industry standards?

Zhejiang ChiMin Pharm's total debt-to-equity ratio is 47.98%.

What is Zhejiang ChiMin Pharm's return on investment on a TTM basis?

Zhejiang ChiMin Pharm's trailing twelve months (TTM) return on investment (ROI) is -5.37%.

Did Zhejiang ChiMin Pharm gain or lose cash last quarter?

In the latest quarter, Zhejiang ChiMin Pharm's net change in cash was 222.17 million.

What were Zhejiang ChiMin Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Zhejiang ChiMin Pharm reported total assets of 2,593.83 million and total liabilities of 683.92 million.

How has Zhejiang ChiMin Pharm's total revenue grown this year?

Zhejiang ChiMin Pharm's total revenue was 93.06 in the previous quarter and 181.02 in the latest quarter.

What is Zhejiang ChiMin Pharm's gross margin on a TTM basis?

Zhejiang ChiMin Pharm's trailing twelve months (TTM) gross margin is 33.93%.

What was Zhejiang ChiMin Pharm's revenue per share for the latest quarter?

Zhejiang ChiMin Pharm's revenue per share for the latest quarter was 6.47.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.